Literature DB >> 9353230

Poxviruses as expression vectors.

M W Carroll1, B Moss.   

Abstract

Poxviruses are widely used for the cytoplasmic expression of recombinant genes in mammalian cells. Recent improvements allow high expression and simplify the integration of multiple foreign genes. Vaccinia virus mutants and other poxviruses that undergo abortive infection in mammalian cells are receiving special attention because of their diminished cytopathic effects and increased safety. New replicating and 'non-replicating' vectors, encoding the bacteriophage T7 RNA polymerase for transcription of recombinant genes, have been engineered.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353230     DOI: 10.1016/s0958-1669(97)80031-6

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  22 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans.

Authors:  Masanori Terajima; Laura Orphin; Anita M Leporati; Pamela Pazoles; John Cruz; Alan L Rothman; Francis A Ennis
Journal:  Hum Immunol       Date:  2008-10-26       Impact factor: 2.850

3.  Primary Human B Cells at Different Differentiation and Maturation Stages Exhibit Distinct Susceptibilities to Vaccinia Virus Binding and Infection.

Authors:  Nicole Shepherd; Jie Lan; Wei Li; Sushmita Rane; Qigui Yu
Journal:  J Virol       Date:  2019-09-12       Impact factor: 5.103

4.  Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.

Authors:  Laurie E Harrington; Robbert van der Most Rv; J Lindsay Whitton; Rafi Ahmed
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 5.  Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens.

Authors:  Magdalini Moutaftsi; David C Tscharke; Kerrie Vaughan; David M Koelle; Lawrence Stern; Mauricio Calvo-Calle; Francis Ennis; Masanori Terajima; Gerd Sutter; Shane Crotty; Ingo Drexler; Genoveffa Franchini; Jon W Yewdell; Steven R Head; Janice Blum; Bjoern Peters; Alex Sette
Journal:  Future Microbiol       Date:  2010-02       Impact factor: 3.165

Review 6.  Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Authors:  Monica Vaccari; Poonam Poonam; Genoveffa Franchini
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

7.  Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging.

Authors:  Jorge E Osorio; Keith P Iams; Carol U Meteyer; Tonie E Rocke
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

Review 8.  Human immunodeficiency virus vaccine trials.

Authors:  Robert J O'Connell; Jerome H Kim; Lawrence Corey; Nelson L Michael
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

9.  Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity.

Authors:  Wenjin Guo; Brad Cleveland; Thaddeus M Davenport; Kelly K Lee; Shiu-Lok Hu
Journal:  Protein Expr Purif       Date:  2013-05-09       Impact factor: 1.650

10.  CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.

Authors:  Liusong Yin; J Mauricio Calvo-Calle; John Cruz; Frances K Newman; Sharon E Frey; Francis A Ennis; Lawrence J Stern
Journal:  J Immunol       Date:  2013-05-10       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.